Upon DNA damage, ataxia telangiectasia mutated (ATM) kinase triggers multiple events to promote cell survival and facilitate repair. If damage is excessive, ATM stimulates cytokine secretion to alert neighboring cells and apoptosis to eliminate the afflicted cell. ATM augments cell survival by activating nuclear factor (NF)-kB; however, how ATM induces cytokine production and apoptosis remains elusive. Here we uncover a p53-independent mechanism that transmits ATM-driven cytokine and caspase signals upon strong genotoxic damage. Extensive DNA lesions stimulated two sequential NF-kB activation phases, requiring ATM and NEMO/IKK-g: The first phase induced TNF-a-TNFR1 feedforward signaling, promoting the second phase and driving RIP1 phosphorylation. In turn, RIP1 kinase triggered JNK3/MAPK10-dependent interleukin-8 secretion and FADD-mediated proapoptotic caspase-8 activation. Thus, in the context of excessive DNA damage, ATM employs NEMO and RIP1 kinase through autocrine TNF-a signaling to switch on cytokine production and caspase activation. These results shed light on cell-fate regulation by ATM.
INTRODUCTION
Metazoan cells are capable of maintaining genomic integrity despite frequent exposure to exogenous or endogenous genotoxic insults. This capacity is mediated by a specialized DNA-damage response (DDR), which is essential for tissue homeostasis and avoidance of malignancy. The DDR involves a network of sensing and signaling components that detect DNA lesions and orchestrate their repair (Harper and Elledge, 2007; Jackson and Bartek, 2009; Kastan and Bartek, 2004; O'Driscoll and Jeggo, 2006; Shiloh, 2003 Shiloh, , 2006 . The DDR also engages signaling pathways to arrest cell growth and promote survival during repair or, alternatively, if lesions are excessive, to alarm neighboring cells and eliminate the damaged cell by programmed death.
Cancer treatment often relies on genotoxic strategies such as ionizing radiation and certain types of chemotherapy. Many treatments induce a specific type of DNA lesion, characterized by double-strand breaks (DSBs). The primary transducer of the response to DSBs is the nuclear kinase ataxia telangiectasia mutated (ATM) (Kastan and Bartek, 2004; O'Driscoll and Jeggo, 2006; Shiloh, 2003 Shiloh, , 2006 . Upon detection of DSBs, ATM is rapidly activated to phosphorylate multiple target proteins on serine or threonine residues followed by glutamine (SQ/TQ motif). ATM thereby mobilizes an array of events, facilitating recognition and repair of DSBs, engagement of cell-cycle checkpoints, and activation of prosurvival and stress-response pathways. Depending on the extent and duration of DNA damage, ATM can also activate cytokine secretion and programmed cell death (Fumagalli and d'Adda di Fagagna, 2009; Harper and Elledge, 2007; Kastan and Bartek, 2004; O'Driscoll and Jeggo, 2006; Rashi-Elkeles et al., 2006; Shiloh, 2003 Shiloh, , 2006 ).
An important signaling cascade activated by ATM is the NF-kB pathway, which regulates genes involved in diverse biological functions, including inhibition of apoptosis and promotion of cell survival (Criswell et al., 2003; Huang et al., 2003; Li et al., 2001; Piret et al., 1999) . ATM-induced NF-kB signaling is implicated not only in permitting normal cells to repair DNA but also in enabling malignant cells to resist genotoxic therapy (Janssens and Tschopp, 2006) . The mechanism underlying NF-kB activation by ATM shares some features with the mode of NF-kB stimulation by the proinflammatory ligand tumor necrosis factor a (TNF-a). Upon binding to its type 1 cell-surface receptor (TNFR1), TNF-a assembles a proximal signaling complex, consisting of several components (Chen and Goeddel, 2002; Hayden and Ghosh, 2008; Karin, 2006; Karin and Lin, 2002; Wilson et al., 2009 ). These include the adaptor, TNFR-associated death domain (TRADD); the DD-containing serine/threonine (S/T) kinase, receptor-interacting protein 1 (RIP1); and the E3 ubiquitin ligases, TNF receptor-associated factor 2 (TRAF2) and cellular inhibitor of apoptosis protein (cIAP) 1 and 2. TNFR1 triggers cIAP-mediated, K63-linked polyubiquitylation of RIP1, promoting RIP1 interaction with TAK1 kinase and TAK1-binding proteins 1 and 2. TAK1 stimulates inhibitor of kB (IkB) kinase (IKK), which consists of the catalytic subunits IKK-a and b and the regulatory subunit IKK-g (NEMO) . A universal requirement of RIP1 for TNF-a-induced NF-kB activation has been challenged . Upon TNFR1 activation, IKK mediates IkB phosphorylation, leading to IkB ubiquitylation and proteasomal degradation. This allows NF-kB to enter the nucleus and activate gene transcription.
ATM is essential for NF-kB activation in response to DNA damage (Li et al., 2001; Piret et al., 1999; Rashi-Elkeles et al., 2006) . Initial studies suggested that DNA lesions induce ATM-dependent NEMO phosphorylation and subsequent ubiquitylation to activate the cytoplasmic IKK complex (Bartek and Lukas, 2006; Huang et al., 2003; Janssens and Tschopp, 2006; Wu et al., 2006) . More recent evidence indicates that nuclear exit of ATM also drives NEMO ubiquitylation, leading to TAK1 phosphorylation and IKK activation (Hinz et al., 2010; Wu et al., 2010) . In contrast to the TNF-a pathway, DDR-driven IkB degradation in mouse embryo fibroblasts did not require TNFR1, TRAF2, TRAF5, or FADD (Hur et al., 2003) . NEMO also forms a tripartite complex with RIP1 and p53-inducible DD-containing protein (PIDD), augmenting NEMO ubiquitylation and NF-kB activation (Janssens et al., 2005) . Alternatively, PIDD binds caspase-2 via the adaptor RIP1-associated protein with a DD, forming a ''PIDDosome'' that induces apoptosis (Janssens and Tschopp, 2006; Tinel and Tschopp, 2004) .
NEMO associates with RIP1, which is reported to be required for DDR-induced NF-kB activation in mouse embryo fibroblasts but not human HEPG2 cells (Hinz et al., 2010; Hur et al., 2003) . RIP1 is implicated not only in controlling NF-kB but also in regulating cell death in response to TNF-a, viral infection, or cIAP antagonists (Bertrand et al., 2008; Cho et al., 2009; He et al., 2009; Petersen et al., 2007; Varfolomeev et al., 2007; Wang et al., 2008) . Kinase activity of RIP1 is dispensable for NF-kB activation (Kelliher et al., 1998; Ting et al., 1996) but required for induction of necroptotic cell death (Cho et al., 2009; Degterev et al., 2008; He et al., 2009; Hur et al., 2003) . RIP1 ubiquitylation favors downstream prosurvival signaling via NF-kB over cell death induction through the adaptor Fas-associated death domain (FADD) and the apoptosis-initiating protease caspase-8 (C8) (Declercq et al., 2009; Wang et al., 2008) .
Despite the critical relevance of the DDR to physiology and disease, little is known about how cellular life or death decisions are made upon ATM activation. In the present work we identify a p53-independent mechanism that selectively triggers ATMinduced cytokine secretion and caspase activation in the context of extensive DNA damage. Our results provide insight into the control of cell fate downstream of ATM.
RESULTS
Extensive DNA Damage Induces ATM-Dependent Interaction of NEMO, RIP1, FADD, and Caspase-8, Leading to Caspase Activation To investigate how ATM controls cellular outcome in response to different levels of DNA damage, we treated HeLa cells with the topoisomerase II inhibitor etoposide and analyzed interactions between potentially relevant intracellular signaling components. Etoposide caused significant formation of DSBs, indicated by phosphorylation of H2AX, BRCA1, SMC-1, and the ATM substrate KAP1 (Figures S1A and S1B available online and Figures 1A and 1B) (Shiloh, 2006) . Etoposide also induced NF-kB activation, detectable within 2 hr by immunoblot (IB) analysis of IkB degradation; furthermore, at high doses and upon longer incubation, etoposide stimulated phosphorylation of stress-activated c-Jun N-terminal kinase (JNK) (Figures 1A and 1B) . Consistent with previous data (Hur et al., 2003) , etoposide triggered association of NEMO with RIP1 ( Figures 1C and 1E ). NEMO-RIP1 interaction and IkB degradation occurred in concert with apparent ubiquitylation of NEMO ( Figure S1C )-a modification known to be important for NF-kB activation in response to DSBs (Huang et al., 2003; Hinz et al., 2010) . Surprisingly, at higher doses and on longer incubation, etoposide also stimulated recruitment of FADD to NEMO-RIP1 complexes ( Figures 1C and 1E ) and association of RIP1 with FADD and C8 ( Figures 1D and 1F ). FADD binds RIP1 and C8 via respective DD and death effector domain (DED) interactions (Wilson et al., 2009) . C8 activation involves self-processing between the p18 and p10 subunits to form a p43 fragment, whereas cleavage between p18 and the DEDs releases C8 from FADD (Boatright et al., 2003) . The pan caspase inhibitor zVAD-fmk (zVAD) efficiently blocks the latter but not the former event (unpublished data). Consistent with this, zVAD augmented association of FADD and RIP1 with NEMO and with C8 ( Figures 1G and 1H) ; reciprocal immunoprecipitation (IP) of FADD or RIP1 further confirmed their interaction ( Figure 1I , Figure S1D ).
The recruitment of FADD and C8 appeared to be functionally significant because IP of C8 revealed C8 processing into p43 and a marked elevation in C8 enzymatic activity, specifically in response to high-dose etoposide ( Figure 1H and Figure 2A ). zVAD did not affect H2AX and KAP1 phosphorylation or p43 generation ( Figure S1B and Figure 2B ), nor did it change the cellular levels of NEMO, RIP1, FADD, or C8 ( Figure S1E ). However, zVAD blocked further C8 processing and consequent activation of caspase-3 (C3), as indicated by attenuated cleavage of C3 and its substrate, PARP; in contrast, zVAD slightly enhanced stimulation of NF-kB and JNK ( Figure 2B ). Consistent with its lack of effect on p43 generation, zVAD did not decrease C8 activity in FADD IPs ( Figure S1F ). Due to antibody (Ab) cross-reactivity, we were unable to visualize C8 by IB in NEMO IPs. Nevertheless, C8 activity was readily detectable by NEMO IP, and this was blocked by siRNA silencing of NEMO ( Figure 2C) ; moreover, C8 activity was detected by RIP1 IP ( Figure S1G ). C8 depletion by siRNA further verified specific C8 association with FADD and RIP1 and C8 activation ( Figures S1H and S1I ). Together, these results suggest that high-dose etoposide induces a functional interaction of NEMO, RIP1, FADD, and C8.
Ionizing radiation, neocarcinostatin, doxorubicin, or camptothecin also induced recruitment of FADD and C8 to RIP1, as well as NF-kB and JNK activation ( Figures S2A and S2B ), demonstrating that other DSB inducers stimulate similar events. Moreover, high-dose etoposide triggered association between RIP1 and C8 and C8 activation also in MDA231 and MDA435 cells ( Figures S2C and S2D ), extending these effects to other cell types. p53 is an important mediator of ATM signals in response to DSBs (Miyashita et al., 1994; Nakano and Vousden, 2001; Oda et al., 2000) . Given that HeLa, MDA231 and MDA435 cells lack functional p53, we turned to RKO cells, which express wild-type p53, to assess p53's involvement in these latter events. Silencing of p53 by siRNA did not significantly affect JNK activation in response to high-dose etoposide, or recruitment of FADD and C8 to RIP1, or C8 activation ( Figures  S2E-S2G ). In contrast, the ATM-specific inhibitor Ku-55933 (Hickson et al., 2004) , which blocked KAP1 phosphorylation and apparent NEMO ubiquitylation ( Figure S1C ), attenuated IkB degradation and JNK phosphorylation ( Figure 2D ). ATM inhibition also suppressed the recruitment of FADD and RIP1 to NEMO and C8 IPs as well as C8 activation ( Figures 2E-2G ). We obtained similar results upon ATM depletion by siRNA ( Figures 2H-2J ). Thus, stimulation of NF-kB, JNK, and C8 in response to high-dose etoposide requires ATM but not p53.
NEMO and RIP1 Operate Upstream of Cytokine Secretion and C8 Activation Next, we investigated whether NEMO and RIP1 are required for ATM-mediated C8 activation. Consistent with the previous implication of NEMO in ATM-mediated NF-kB activation, knockdown of NEMO by siRNA abolished etoposide-stimulated IkB degradation; moreover, NEMO depletion also inhibited JNK activation ( Figure 3A ). Persistent DNA lesions promote cellular secretion of proinflammatory cytokines such as interleukin (IL)-6 and IL-8 via NF-kB (Fumagalli and d'Adda di Fagagna, 2009; Linard et al., 2004; Rodier et al., 2009; Zhou et al., 2001) . We confirmed ATM-dependent secretion of IL-6 and IL-8 in response to high-dose etoposide ( Figures S3A-S3F ). NEMO knockdown inhibited generation of both cytokines ( Figures 3B and  3C) ; furthermore, it blocked recruitment of FADD and RIP1 to NEMO and C8 IPs as well as C8 activation ( Figures 3D-3F ). RIP1 siRNA also inhibited these latter events (Figures 3G-3J), with comparable effects in MDA231 cells ( Figures S3G-S3I ). By contrast, p53 silencing in RKO cells did not significantly inhibit IL-8 secretion ( Figure S2H ), consistent with other data (Rodier et al., 2009) . Hence, NEMO and RIP1 operate upstream of both cytokine secretion and C8 activation in response to extensive DNA damage. Knockdown of RIP1 or C8 by siRNA similarly attenuated etoposide-induced cell death (Figures S3J and S3K) , confirming that C8 activation is mediated primarily by RIP1 and contributes significantly to this cellular outcome.
NF-kB Stimulation by ATM Controls Both JNK-Mediated Cytokine Secretion and JNK-Independent C8 Activation
The IKK inhibitor BMS-345541 blocked IkB degradation, as well as JNK activation and IL-8 secretion, in response to high-dose etoposide (Figures 4A and 4B) . IKK inhibition also attenuated the recruitment of FADD and RIP1 to NEMO and C8 IPs as well as C8 activation ( Figures 4C-4E ). We obtained similar results by siRNA silencing of the NF-kB subunit p65/RelA ( Figures  S4A-S4D ). Consistent with these findings, IKK inhibition suppressed cell-death induction by etoposide ( Figure S4E ). The JNK inhibitor SP600125 did not prevent etoposide-induced IkB degradation yet blocked JNK phosphorylation and IL-8 secretion ( Figures 4F and 4G ). In contrast, JNK inhibition did not substantially affect association of FADD with NEMO and RIP1, interaction of RIP1 and FADD with C8, or C8 activation ( Figures  4H-4J ). Depletion of JNK1 or JNK2 by siRNA did not significantly inhibit IL-8 secretion or C8 activation (data not shown). However, knockdown of JNK3/MAPK10 attenuated IL-8 secretion without significantly affecting IkB degradation, association of RIP1 and FADD with C8, or C8 activation ( Figures S4F-S4I ). These results suggest that NF-kB activation occurs upstream of both JNK stimulation and FADD recruitment: JNK3 supports IL-8 secretion, whereas FADD independently mediates C8 activation.
RIP1 Kinase Activity Is Required for IL-8 Secretion as well as C8 Stimulation
To assess whether any of the latter events depends on RIP1 kinase activity, we used the RIP1-specific inhibitor Necrostatin1 (Nec1) (Degterev et al., 2008 , and see below). Nec1 did not alter H2AX or KAP1 phosphorylation in response to high-dose etoposide; however, it partially blocked IkB degradation and JNK phosphorylation ( Figure 5A , Figure S5A ). Unexpectedly, we detected two phases of NF-kB activation, evident by an initial wave of RelA/p65 phosphorylation and IkB degradation at 2-6 hr, followed by a second wave at 12-20 hr (Figures 5B and 5C) . Although the level of activation was comparable during both phases, pretreatment with Nec1 selectively inhibited the second but not the first phase ( Figures 5B and 5C ). Nec1 strongly attenuated etoposide-induced mRNA transcription of TNF-a and IL-8 at 27 hr but not at 7 hr (Figures S5B and S5C) , consistent with its selective inhibition of the second but not the first NF-kB phase. These data confirm earlier work in HeLa cells were treated with various etoposide doses for 20 hr and subjected to C8 IP followed by either IB analysis (A, top) or C8 enzymatic activity assay (A, bottom). (B) Cells were treated with zVAD (20 mM) or DMSO for 4 hr, followed by 100 mM etoposide for 20 hr. Cell lysates were analyzed by IB as indicated. (C) HeLa cells were transfected with control or NEMO siRNA for 48 hr, followed by treatment with 100 mM etoposide for 20 hr. Cell lysates were analyzed by NEMO IP, followed by C8 activity assay. (D-G) HeLa cells were pretreated with the ATMspecific inhibitor Ku-55933 (ATMi) or vehicle plus zVAD for 4 hr, followed by treatment with 100 mM etoposide for 20 hr. Cell lysates were analyzed by IP and/or IB as indicated (D-F) or by C8 IP and activity assay (G). (H-J) Cells were transfected with ATM or control siRNA for 48 hr, followed by treatment with 100 mM etoposide for 20 hr, and analyzed by IB as indicated (H) or by C8 IP, followed by IB (I) or by C8 activity assay (J). Pretreatment with zVAD was included before etoposide addition. See also Figure S2 .
which IkB was monitored up to 9 hr after genotoxic exposure (Hur et al., 2003) ; however, they reveal a second phase of NF-kB induction in response to highdose etoposide, which uniquely depends on RIP1 kinase activity. Nec1 also inhibited etoposide-driven IL-8 secretion (Figure 5D ). In contrast, Nec1 did not block RIP1 association with NEMO ( Figure 5E ), consistent with its lack of effect on early NF-kB activation. However, Nec1 did prevent association of FADD with NEMO and RIP1, interaction of FADD and RIP1 with C8, or C8 activation ( Figures 5E-5G ). We observed similar Nec1 effects in MDA231 and MDA435 cells ( Figures S5D-S5F and data not shown). Hence, RIP1 kinase activity is important for both IL-8 secretion and C8 stimulation.
Nec1 inhibits RIP1 autophosphorylation (Degterev et al., 2008) . To verify its selectivity, we tested Nec1 on a preassembled panel of 98 diverse kinases, using the KINOMEscan technology (Table S1A) . As compared to its complete inhibition of RIP1, Nec1 inhibited two other kinases, namely, PAK1 and PKAca, by more than 60%. Depletion of PAK1 or PKAca by siRNA did not inhibit IL-8 secretion or interaction of RIP1 and FADD with C8 in response to high-dose etoposide (Figures S5G-S5J ). Furthermore, Nec1 bound tightly to RIP1 but not to RIP2 or RIP4 (Table S1B) , consistent with other evidence of its selectivity for RIP1 over RIP2, 3, or 4 (Degterev et al., 2008) .
To examine whether RIP1 undergoes phosphorylation in response to high-dose etoposide, we took advantage of RIP1's character as an S/T-kinase by screening a panel of available anti-phospho-S/T antibodies for ability to detect RIP1 upon IP and IB (see Experimental Procedures). One of the antibodies (clone 100G7E) specifically revealed robust RIP1 phosphorylation by 22 hr in response to 100 mM but not 10 mM etoposide ( Figures 5H and 5I ). Silencing of ATM or NEMO by siRNA attenuated RIP1 phosphorylation, as did IKK inhibition ( Figures 5J-5L) . The anti-phospho-SQ/TQ antibody did not react with RIP1 (data not shown), suggesting that RIP1 is not a direct substrate for ATM. Nec1 suppressed RIP1 phosphorylation ( Figure 5M ), whereas knockdown of PAK1 or PKAca did not ( Figures S5K and S5L) . Furthermore, ectopic expression of a kinase-domain-deficient RIP1 mutant (D300), albeit less abundant than endogenous RIP1 expression, significantly attenuated RIP1 phosphorylation ( Figure 5N) . Consistent with the Nec1 data, D300 inhibited IL-8 secretion, recruitment of FADD to RIP1 and NEMO, and C8 activation in response to high-dose etoposide ( Figures S5M-S5P) . Importantly, phosphorylated RIP1 was associated with NEMO and FADD, and vice versa, FADD was detectable upon RIP1 IP with anti-phospho-S/T antibody ( Figures 5O-5Q ). These results suggest that RIP1 undergoes phosphorylation in response to high-dose etoposide-a modification that depends upon ATM, NEMO, and IKK and drives both IL-8 secretion and C8 activation. We were intrigued by the high-molecular-mass RIP1 species induced at high doses of etoposide ( Figures 1C-1H) ; these species disappeared upon siRNA knockdown of RIP1 ( Figure 3H ), suggesting RIP1 polyubiquitylation. RIP1 IP under denaturing conditions and IB against ubiquitin confirmed this possibility (Figure S6A) . Further analysis revealed K63-rather than K48-linked polyubiquitylation of RIP1 ( Figure S6B ). Genetic ablation of cIAPs or induction of their proteasomal destruction by Smac-mimetics prevents TNF-a-induced RIP1 polyubiquitylation, disrupting NF-kB activation and promoting cell-death signaling via FADD and C8 (Bertrand et al., 2008; Cho et al., 2009; Declercq et al., 2009; He et al., 2009; Petersen et al., 2007; Varfolomeev et al., 2007) . Hence, to probe the involvement of RIP1 ubiquitylation in the response to DNA damage, we used the bivalent IAP antagonist BV6 (Varfolomeev et al., 2007 (Varfolomeev et al., , 2008 . BV6 blocked etoposide-induced RIP1 K63 polyubiquitylation as well as IkB degradation, but not KAP1 phosphorylation ( Figures S6C-S6E ). In the absence of etoposide, BV6 induced a modest, yet detectable, association of RIP1 and FADD with C8 and a measurable increase in C8 activation (Figures S6F and S6G) . Upon etoposide treatment, BV6 further enhanced association of RIP1 and FADD with C8, processing of C8 into p43, and C8 activation, as well as cell death (Figures S6F-S6H ). Consistent with these data, siRNA knockdown of cIAP2 augmented etoposide-induced association of RIP1, FADD, and C8, as well as C8 activation ( Figures S6I and S6J) . Thus, although cIAP-mediated RIP1 polyubiquitylation supports NFkB activation, it opposes the recruitment of FADD and C8 to RIP1. Nec1 abolished the appearance of ubiquitylated RIP1 in NEMO IPs (Figure 5E ), indicating that RIP1 kinase activation occurs upstream of RIP1 ubiquitylation.
TNF-a-TNFR1 Feedforward Signaling Mediates the Induction of IL-8 Secretion and C8 Activation
We reasoned that initial NF-kB activation downstream of ATM might turn on positive feedforward signals that could re-engage NEMO and RIP1 kinase to drive IL-8 secretion and C8 activation in the context of persistent DNA damage. TNF-a was a plausible candidate for mediating such signals because it can be induced via NF-kB and is also capable of activating NF-kB and of engaging RIP1 via TNFR1. Indeed, exposure to high doses of etoposide or prolonged incubation with the drug induced significant accumulation over time of secreted TNF-a in cell supernatants ( Figures 6A and 6B) . We observed initial upregulation of TNF-a mRNA (62-fold) by 6 hr, followed by massive further induction (6900-fold) at 26 hr ( Figure 6C ). IKK inhibition blocked TNF-a secretion ( Figure 6D ), indicating that this event is driven primarily by NF-kB. JNK inhibition partially attenuated TNFa production (data not shown), suggesting that JNK signaling may coamplify this response.
To assess the functional significance of TNF-a secretion, we tested the effect of a soluble TNFR1-Fc decoy receptor. TNFR1-Fc inhibited the late (20 hr) but not the early (2 hr) phase of etoposideinduced NF-kB activation, as well as JNK phosphorylation ( Figure 6E ). TNFR1-Fc also suppressed RIP1 phosphorylation, RIP1 polyubiquitylation, and IL-8 secretion ( Figures 6F-6H ). Although not preventing RIP1 binding to NEMO at 2 hr, TNFR1-Fc partially attenuated this interaction at 20 hr, blocking FADD binding, as well as recruitment and activation of C8 (Figures 6I-6K ). We obtained similar results by siRNA depletion of TNFR1 ( Figures 6L-6P ) or with anti-TNF-a neutralizing antibody (Figures S6K and S6L ). Consistent with these findings, TNFR1-Fc significantly inhibited induction of cell death by high-dose etoposide ( Figure S6M ). Hence, an autocrine TNF-a-TNFR1 feedforward loop supports the second wave of NF-kB stimulation and re-engages RIP1 kinase in conjunction with NEMO to trigger IL-8 secretion and C8 activation.
DISCUSSION
Metazoan homeostasis requires an effective ability to respond to the frequent DNA damage inflicted by environmental or endogenous insults. Whereas successful resolution of DNA lesions enables cells to continue to perform their normal functions and (H) Cells were treated with 100 mM etoposide for 20 hr, and cell lysates were analyzed by RIP1 IP followed by IB using phospho-S/T Ab (clone 100G7E, see Experimental Procedures). (I) Cells were treated with indicated etoposide doses for 2 hr or 22 hr, and cell lysates were analyzed as in (H). (J and K) Cells were transfected with control, ATM (J), or NEMO siRNA (K) for 48 hr, followed by treatment with 100 mM etoposide for 20 hr, and analyzed as in (H). (L and M) Cells were pretreated with IKKi (5 mM) versus vehicle (L) or Nec1 (30 mM) versus vehicle (M) for 4 hr, followed by treatment with 100 mM etoposide for 20 hr, and analyzed as in (H). (N) Cells were transfected with the D300 RIP1 deletion construct or empty vector for 24 hr, followed by treatment with 100 mM etoposide for 20 hr, and analyzed as in (H).
(O-Q) Cells were treated with 100 mM etoposide for 20 hr and analyzed by NEMO (O) or FADD (P) IP followed by IB using phospho-S/T Ab. Vice versa, cell lysates were analyzed by IP using phospho-S/T Ab followed by IB with RIP1 and FADD Ab (Q). Pretreatment with zVAD was included before etoposide addition. Error bars in (D) represent mean ± SD of duplicates. See also Figure S5 and Table S1. hence the organism to thrive, excessive damage can lead to genomic instability syndromes, malignant cell transformation, and cancer (Harper and Elledge, 2007; Jackson and Bartek, 2009; Kastan and Bartek, 2004; O'Driscoll and Jeggo, 2006; Shiloh, 2003 Shiloh, , 2006 . Mechanisms to eliminate cells harboring extensive DNA lesions have evolved alongside DNA repair functions. Thus, defining the molecular events that orchestrate an effective DDR is important not only for understanding homeostasis but also for developing effective approaches to treat diseases associated with DNA damage.
In response to DSBs, ATM activation sets forth multiple signals to arrest cell-cycle progression and promote cell survival, enhancing the cell's ability to repair the damage. Alternatively, ATM may direct the cell toward an apoptotic fate if the damage to DNA is excessive or persistent. ATM activates p53, which controls both cell-cycle checkpoints and apoptosis via transcriptional as well as nontranscriptional mechanisms (Miyashita et al., 1994; Nakano and Vousden, 2001; Oda et al., 2000) . However, little is known about how ATM controls cell fate in coordination with the extent of genotoxic damage. Key among the signaling cascades engaged by ATM is the NF-kB pathway, activated through nuclear as well as cytoplasmic events (Bartek and Lukas, 2006; Hinz et al., 2010; Huang et al., 2003; Hur et al., 2003; Janssens and Tschopp, 2006; Wu et al., 2006 Wu et al., , 2010 . NF-kB is generally viewed as a prosurvival factor; however, there is some evidence that it may facilitate proapoptotic signals under certain circumstances, through repression of prosurvival genes or upregulation of proapoptotic factors (Baud and Karin, 2009; Hayden and Ghosh, 2008; Karin, 2006; Papa et al., 2006) . Indeed, activation of NF-kB and AP-1 in response to genotoxic stress induces apoptosis of T lymphocytes via upregulation of Fas/CD95 ligand (Kasibhatla et al., 1998) . NF-kB also mediates proinflammatory cytokine secretion in the context of persistent DNA lesions-a process dubbed senescence-associated secretory phenotype (Fumagalli and d'Adda di Fagagna, 2009; Rodier et al., 2009) . However, the underlying molecular interactions have not been well defined. Our study reveals that NF-kB activation by ATM sets up a p53-independent signaling mechanism that enables the cell to switch on a new set of events in the face of strong genotoxic stress.
To model extensive DNA damage, we used concentrations of the DSB-inducing agent etoposide that mimic peak plasma levels in cancer patients receiving high-dose chemotherapy (Hande et al., 1984) . Phosphorylation of H2AX, KAP1, and other DDR markers confirmed extended induction of DSBs and ATM activation. We discovered that a NEMO-RIP1 complex, which is induced also in response to low levels of DNA damage, continues to assemble in the presence of extensive DSBs. Under the latter circumstance, NEMO-RIP1 interaction triggers two important new functions: (1) stimulation of JNK phosphorylation, leading to IL-8 production; and (2) recruitment of FADD and C8, leading to C8 activation. Knockdown of NEMO or RIP1 blocked both of these functions, as did pharmacologic inhibition of IKK or siRNA silencing of RelA/p65, indicating that not only NEMO and RIP1 but also NF-kB-dependent signals are required to drive these events. Further studies demonstrated that JNK3 is critical for IL-8 induction but not for C8 activation. These results provide direct evidence supporting the previous notion that NF-kB mediates cytokine secretion in response to persistent DSBs (Fumagalli and d'Adda di Fagagna, 2009) and reveal that this function depends nonredundantly on JNK3.
To determine what switches on the new effects of NEMO-RIP1 interaction in response to strong DNA damage, we examined the role of RIP1 phosphorylation and/or ubiquitylation. We found that high-dose etoposide induces two consecutive phases of NF-kB activation. Consistently with other work (Hur et al., 2003) , the selective RIP1 kinase inhibitor Nec1 did not block the initial phase, indicating that RIP1 kinase activity is dispensable for this function. However, Nec1 inhibited the second phase, demonstrating that RIP1 kinase activity supports this additional wave of NF-kB stimulation. Nec1 also inhibited JNK phosphorylation and IL-8 secretion, as well as recruitment of FADD and C8 to RIP1 and C8 activation, placing RIP1 kinase activity upstream of these events. Importantly, RIP1 phosphorylation, which occurred in an ATM-and NEMO-dependent manner, was detectable only in response to strong DNA damage, in conjunction with the second NF-kB activation phase. Moreover, phosphorylated RIP1 associated with NEMO and FADD, supporting the involvement of RIP1 kinase in C8 activation. RIP1 likely undergoes autophosphorylation, given that its modification was inhibited by Nec1 and by an ectopically expressed RIP1 mutant lacking the kinase domain. We have been unable to map the RIP1 phosphorylation site(s) by mass spectrometry, due to difficulty with purifying the protein from overexpression systems. We also detected polyubiquitylated RIP1 in association with NEMO at late time points after induction of strong DNA damage. Inhibition of this RIP1 modification with BV6 or by siRNA knockdown of cIAP2 augmented the recruitment of FADD and C8 to RIP1 and C8 activation, suggesting that RIP1 ubiquitylation does not favor the latter events. This finding is consistent with other evidence that RIP1 ubiquitylation interferes with recruitment of FADD and C8 in response to TNF-a (Wang et al., 2008) . On the other hand, BV6 also inhibited NF-kB activation, in keeping with the role of K63-linked RIP1 ubiquitylation in NF-kB activation by TNF-a (Wertz and Dixit, 2008) . RIP1 phosphorylation was blocked by NF-kB inhibition and occurred during the second wave of NF-kB activity. This prompted us to investigate whether the initial NEMO-RIP1 interaction induces a positive reinforcement loop to re-engage RIP1 kinase. Two lines of evidence indicated that such a mechanism is mediated by autocrine TNF-a-TNFR1 feedforward signaling: First, high-dose etoposide induced NF-kB-dependent TNF-a production, which was detectable by 6 hr yet greatly accelerated over time. JNK inhibition partially attenuated TNF-a induction, suggesting that JNK signaling coamplifies TNF-a upregulation. Second, whereas intervention with TNF-a signaling spared initial NEMO-RIP1 association and early NF-kB activation, it disrupted further NEMO-RIP1 binding, RIP1 phosphorylation, RIP1 ubiquitylation, and subsequent NF-kB stimulation. TNF-a blockade also inhibited the downstream events linked to IL-8 secretion, C8 activation, and cell death. A requirement for sufficient TNF-a accumulation to drive the TNFR1-mediated feedforward loop likely explains the observed lag in RIP1 phosphorylation. Moreover, the first NF-kB activation phase induced by DNA lesions is typically slower than NF-kB stimulation by TNF-a (Janssens and Tschopp, 2006) , which may further contribute to the delay in RIP1 modification.
Taken together with other findings, our studies suggest the following model for cell-fate regulation in response to DNA damage ( Figure 7) . As previously established, in response to low levels of DSBs, ATM stimulates an early phase of NF-kB activity in a NEMO-dependent yet TNFR1-independent manner, promoting transcription of several well-established prosurvival genes (Karin, 2006; Karin and Lin, 2002; Luo et al., 2005; Rashi-Elkeles et al., 2006) . Indeed, we observed mRNA induction of the prosurvival genes cIAP1 and cFLIP within 6 hr of etoposide addition, and depletion of either protein significantly augmented C8 activation (data not shown). Critically, NF-kB stimulation also sets up an autocrine feedforward signaling loop that involves TNF-a and TNFR1: In the presence of extensive DSBs, this loop is sustained and promotes a second wave of NF-kB signaling, accelerating TNF-a production and driving TNFR1-mediated RIP1 autophosphorylation. In conjunction with NEMO, RIP1 kinase promotes JNK3-mediated induction of IL-8 secretion to alert other cells and recruits FADD to drive C8 activation and cell death. K63-linked polyubiquitylation of RIP1, which occurs following RIP1 phosphorylation, supports the second phase of NF-kB activation but also can counteract FADD-C8 recruitment, raising the possibility that RIP1 ubiquitylation provides a further regulatory node.
C8 is a key mediator of proapoptotic signaling by death receptors (Ashkenazi and Dixit, 1998; Peter and Krammer, 2003; Wilson et al., 2009) . Several studies indicate that C8 can be activated in response to genotoxic stress (Engels et al., 2000; Jones et al., 2001; Sohn et al., 2005; von Haefen et al., 2003; Wesselborg et al., 1999) . Our present work identifies a specific path leading to C8 activation in response to extensive DSBs via NF-kB and TNFR1. The finding that IL-8 secretion occurs in concert with C8 activation raises the possibility that cells destined to die in the context of strong DNA lesions send signals to mobilize other cells in the tissue microenvironment to respond to the damage, for example by helping to remove apoptotic cell debris or to reinforce growth arrest (Acosta et al., 2008; Varfolomeev et al., 2005; Waugh and Wilson, 2008) . The molecular interplay we defined bears intriguing similarity to the mechanism of apoptosis activation by Smac-mimetic drugs, which also engage C8 via NF-kB-mediated induction of TNF-a (Bertrand et al., 2008; Petersen et al., 2007; Varfolomeev et al., 2007) . Our findings provide support for the conclusion that the NF-kB cascade is not merely a prosurvival pathway; rather, NF-kB also has the capacity to set up conditional pro-death In response to a low level of DSBs, ATM activation induces ubiquitylation of NEMO/IKK-g and its interaction with RIP1 and with IKK-a and -b, driving NF-kB activation. This early NF-kB activation phase is independent of RIP1 kinase activity and TNFR1 and promotes cell survival by inducing transcription of antiapoptotic genes such as cIAPs and cFLIP. Another key effect of NF-kB activation downstream of ATM is to set up an autocrine TNF-a-TNFR1 signaling loop. If the damage is resolved, this loop subsides. In contrast, if the level of DSBs is extensive, ATM activity is sustained and the feedforward signaling loop continues to operate. This accelerates further TNF-a production, supporting a second wave of NF-kB activity and driving TNFR1-mediated RIP1 phosphorylation. In turn, RIP1 kinase promotes JNK3-mediated induction of IL-8 production to alert other cells of the damage and recruits FADD to activate C8 and trigger programmed cell death. K63-linked polyubiquitylation of RIP1 by cIAPs, which occurs downstream of RIP1 kinase activation, promotes the second NF-kB activation phase; however, it can also counteract the recruitment of FADD and C8 to RIP1, providing an additional level of regulation. signals, which can be decoded in the context of cellular parameters such as the extent of DNA damage to dictate whether the cell should live or die.
In conclusion, we have identified a NEMO-and RIP1-based switch mechanism involving TNF-a-TNFR1 feedforward signaling that mediates ATM-induced cytokine secretion and caspase activation selectively in the context of severe DNA damage. These results provide important insight into the molecular events that control cell fate downstream of ATM.
